Vol. 52 | No. 1 | January-June 2024Back

Open Access

When Hypertension Gets On One’s Nerves: Has The Time Come For Renal Denervation?

Timothy C. Dy
Jun 2024 DOI 10.69944/pjc.c689bf7bce

More Info

Timothy C. Dy, MD
Chinese General Hospital Heart Institute
Email: timothy.dy@gmail.com


Declaration of conflicts of interest: None.

References
  1. Edwards EW, Saari HD, DiPette DJ, et al. Inadequate hypertension control rates: A global concern for countries of all income levels. J Clin Hypertens. 2022;24:362–364. doi: 10.1111/jch.14444.
  2. Fillipi A, Sangiorgi D, Buda S, et al. How many hypertensive patients can be controlled in “real life”: an improvement strategy in primary care. BMC Fam Pract. 2013;14:192. doi: 10.1186/1471-2296-14-192.
  3. Tapela N, Collister J, Clifton L, et al Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK. Open Heart. 2021;8:e001461. doi: 10.1136/openhrt-2020-001461.
  4. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;9917:622-629. doi: 10.1016/S0140- 6736(13)62192-3.
  5. Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2021. https://doi.org/10.1038/s41440-021-00754-7.
  6. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham controlled trial. Lancet. 2018;391:2335–45.
  7. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.
  8. Schmieder RE, Mahfoud F, Mancia G, Azizi M, Bohm M, Dimitriadis K, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39:1733–41.
  9. Ahmad Y, Kane C, Arnold A et al. Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovascular Revascularization Medicine. 2022; 34: 112-118.
  10. Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K and Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2021. https://doi.org/10.1038/ s41440-021-00760-9.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.